Asthma Drugs Market Report 2026

The asthma drugs market size has grown strongly in recent years. It will grow from $24.93 billion in 2025 to $26.3 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising prevalence of asthma, limited access to advanced therapies, high incidence of respiratory infections, traditional inhaler usage, awareness campaigns by health organizations.

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $33.62 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in biologics & monoclonal antibodies, adoption of smart inhalers, digital health integration, expansion of preventive care programs, increasing pediatric asthma diagnosis. Major trends in the forecast period include personalized asthma treatment, telemedicine & remote patient monitoring, development of biologic and targeted therapies, inhalation device innovation, increased focus on pediatric asthma care.

The increasing prevalence of respiratory diseases is expected to drive the growth of the asthma drug market in the coming years. Respiratory diseases are health conditions that affect the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. A higher prevalence of respiratory diseases increases the use of asthma medications to manage and relieve symptoms associated with these conditions. As respiratory disorders become more common, particularly chronic conditions such as asthma that involve persistent airway inflammation and narrowing, the demand for effective therapeutic treatments continues to rise. For example, in December 2023, a research study published in JAMA Network Open, a medical journal of the American Medical Association, projected that global cases of chronic obstructive pulmonary disease could approach nearly 600 million by 2050, representing a 23% increase in prevalence. Consequently, the growing burden of respiratory diseases is contributing to the expansion of the asthma drug market.

Leading companies operating in the asthma drug market are emphasizing product innovation, including the development of fixed-dose triple-drug combination therapies, to improve lung function, achieve better symptom control, and reduce the frequency of exacerbations in patients with poorly controlled asthma. Fixed-dose triple-drug combinations integrate multiple therapeutic agents into a single inhalation therapy, helping to enhance treatment effectiveness and patient adherence. For instance, in January 2023, Lupin Ltd., an India-based pharmaceutical company, introduced DIFIZMA, a fixed-dose combination of indacaterol, glycopyrronium, and mometasone, for the treatment of inadequately controlled asthma in adults and adolescents aged twelve years and above. Approved by the Drug Controller General of India, DIFIZMA strengthened Lupin’s respiratory portfolio as the only fixed-dose triple-drug combination available for asthma patients requiring improved symptom management. Lupin is engaged in the development and manufacture of a broad range of pharmaceutical products, including inhalation therapies for respiratory diseases.

In February 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed sum. Through this acquisition, GSK obtained access to AIO-001, a potentially best-in-class long-acting anti-thymic stromal lymphopoietin monoclonal antibody that is prepared to enter Phase II clinical development for the treatment of adult asthma patients. The extended half-life of AIO-001 may allow for dosing as infrequently as once every six months, potentially transforming the standard of care, particularly for approximately 40% of patients with severe asthma characterized by low type 2 inflammation. Aiolos Bio is a US-based clinical-stage biotechnology company focused on developing novel asthma therapies.

Major companies operating in the asthma drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd., Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc.

North America was the largest region in the asthma drugs market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the asthma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created challenges for the asthma drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized inhalation devices. This has particularly affected the production and pricing of monoclonal antibodies and combination drugs in North America and Europe. Segments such as curative therapies and advanced biologics face the highest impact, while preventive inhalers see moderate effects. Positively, tariffs are encouraging local manufacturing investments and fostering innovation in cost-effective asthma drug solutions.

The asthma drugs market research report is one of a series of new reports that provides asthma drugs market statistics, including asthma drugs industry global market size, regional shares, competitors with a asthma drugs market share, detailed asthma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the asthma drugs industry. This asthma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Asthma is a chronic respiratory disease caused by inflammation and tightening of the muscles surrounding the airways, which makes breathing difficult for patients. It occurs when the airways become narrowed, swollen, and obstructed by excessive mucus. Asthma drugs play a vital role in the management and control of this condition.

The main types of asthma include allergic and non-allergic asthma. Allergic asthma is a respiratory disorder marked by airway constriction following exposure to allergens, resulting in breathing difficulties. There are various trigger types of asthma, including adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma. Asthma drugs are categorized into classes such as bronchodilators, monoclonal antibodies, anti-inflammatory drugs, and combination drugs, and are used by patients with asthma as well as those with chronic obstructive pulmonary disease (COPD).

The asthma drugs market consists of sales of drugs such as bronchodilators (beta-2 agonists), monoclonal antibodies (omalizumab, mepolizumab), and anti-inflammatory drugs (budesonide, ciclesonide), used for the treatment of asthma in patients of all ages. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.